Orlistat

Green-G

Brand Name(s):Xenical

Indication:Obesity

Rationale:

Considered:Apr-07

Review Date:Jan-20

Comments:
NICE CG189 Obesity: identification, assessment and management of overweight and obesity in children, young people and adults – guidance available at:

http://www.nice.org.uk/guidance/cg189/resources/guidance-obesity-identification-assessment-and-management-of-overweight-and-obesity-in-children-young-people-and-adults-pdf
Nov 2014
…………………………
MHRA Drug Safety Update – Orlistat: theoretical interation with antiretroviral HIV medicines – information found at below link
http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON392868
…………………………

Refer to NICE guidance Obesity – working with local communities PH42 November 2012

European Medicines Agency confirms positive benefit-risk balance of orlistat-containing medicines
Existing information on potential very rare liver-related side effects to be harmonised
Finalising its review on orlistat-containing medicines and the possible risk of severe liver injuries, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has concluded that the benefit of these medicines continue to outweigh their risks in the treatment of obese or overweight patients with a body mass index of 28 kg/m2 or above. The Committee recommended that the product information for these products should be harmonised to ensure that the information on possible very rare liver-related side effects is the same for all orlistat-containing medicines.
16 February 2012 EMA/CHMP/120218/2012 Press Office Press release
…………………………